Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Erythropoietin-producing hepatoma A2 (EphA2), a member of the Eph family of receptor tyrosine kinases, has been implicated in inflammation and atherosclerotic diseases. Because EphA2 has been reported to participate in kidney and cardiovascular diseases, this study aimed to investigate the relationship between serum EphA2 levels and renal function in individuals with IgA nephropathy. In addition, we evaluated the potential of EphA2 as a biomarker reflecting histological severity and treatment response.
Methods: Circulating EphA2 levels were measured by enzyme-linked immunosorbent assay (ELISA) in 102 participants with biopsy-proven IgA nephropathy who underwent tonsillectomy followed by steroid pulse therapy. Blood samples were obtained before renal biopsy and immediately prior to the third course of steroid pulse therapy. Detailed clinical data and pathological data, including demographic characteristics, comorbidities, and Oxford MEST-C scores, were analyzed to assess the association between serum EphA2 levels and histological severity.
Baseline EphA2 levels were positively correlated with histological severity, particularly the degree of global glomerulosclerosis, tubular atrophy, and interstitial fibrosis, and were inversely correlated with estimated glomerular filtration rate (eGFR) prior to biopsy. Multivariate logistic regression analysis revealed that elevated EphA2 was an independent determinant of reduced eGFR (<60 mL/min/1.73 m²), even after adjustment for age, sex, and proteinuria. Although eGFR remained largely unchanged after treatment, both proteinuria and serum EphA2 levels significantly decreased following steroid pulse therapy, indicating a favorable treatment response.
Serum EphA2 demonstrates a strong correlation with both renal function and histological severity and further reflects treatment response in individuals with IgA nephropathy. These findings suggest that EphA2 may serve as a novel biomarker for assessing both kidney impairment and therapeutic efficacy in this population.
